Cargando…

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Detalles Bibliográficos
Autores principales:	Mauri, Gianluca, Patelli, Giorgio, Gori, Viviana, Lauricella, Calogero, Mussolin, Benedetta, Amatu, Alessio, Bencardino, Katia, Tosi, Federica, Bonazzina, Erica, Bonoldi, Emanuela, Bardelli, Alberto, Siena, Salvatore, Sartore-Bianchi, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086435/ https://www.ncbi.nlm.nih.gov/pubmed/37056342 http://dx.doi.org/10.3389/fonc.2023.1147497

Ejemplares similares

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
por: Mauri, Gianluca, et al.
Publicado: (2021)

Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature
por: Patelli, Giorgio, et al.
Publicado: (2021)

Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
por: Mauri, Gianluca, et al.
Publicado: (2023)

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
por: Amatu, Alessio, et al.
Publicado: (2016)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2021)

Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients
por: Patelli, Giorgio, et al.
Publicado: (2022)

The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review
por: Lombardo, Roberta, et al.
Publicado: (2020)

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2017)

Early‐onset colorectal cancer in young individuals
por: Mauri, Gianluca, et al.
Publicado: (2018)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment
por: Amatu, Alessio, et al.
Publicado: (2022)

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
por: Crisafulli, Giovanni, et al.
Publicado: (2022)

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2009)

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
por: Russo, Mariangela, et al.
Publicado: (2018)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2009)

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
por: Amatu, Alessio, et al.
Publicado: (2015)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2023)

Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2013)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management
por: Vallerio, P., et al.
Publicado: (2021)

Arthritogenic Monoclonal Antibodies from K/BxN Mice
por: Maccioni, Mariana, et al.
Publicado: (2002)

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report
por: Metro, Giulio, et al.
Publicado: (2015)

Antiproton-proton annihilations into $\pi^{-}$ and $K^{-}$mesons at 5.7 GeV/c
por: Atherton, Henry W, et al.
Publicado: (1970)

Study of Antiviral Activity of Metabolites of a New Serratia species K-57 Strain
por: Puchkova, L. I., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r79p30sjkc9om3nrj6o6bbs5sg